Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Science and Technology Council, Taiwan | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The project will investigate the effect of pharmacological and electric modulation of N-methyl-D-aspartate (NMDA) pathway on the cognitive flexibility and volitional movement preparation in patients with Parkinson's disease (PD).
Sarcosine (also called N-methylglycine) is an endogenous GlyT-1 inhibitor. By blocking glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor function. NMDA receptor, a subtype of ionotropic glutamate receptors, serves important functions in the brain, including learning, memory, cognition, and neural plasticity under physiological conditions and contributes to neurodegeneration in pathophysiological processes. NMDA receptor represents collectively a group of heteromeric tetramers. Every NMDA receptor is a protein complex, typically composed of two NR1 subunits and two NR2 subunits that together form the NMDA receptor ion channel. It requires two receptor agonists (glutamate for the NR2 binding site and glycine for the NR1 binding site) to open the ion channel for NMDA receptor activation. Clinically, modulation through the NMDA-NR1-glycine site is preferred to avoid the excitotoxicity associated with the glutamate site activation.8 In addition, recent animal studies have shown that dopamine secretion can be enhanced by either blocking the striatal NR2 or by activation of the NMDA-receptor glycine site. In the project, we will focus on pharmacological enhancement of NMDA-glycine receptor function based on increasing synaptic glycine concentration by sarcosine administration to examine whether enhancing NMDA-glycine receptor activity can improve the neuropsychiatric symptoms, cognition and hopefully motor function in PD-D patients
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sarcosine capsule | Experimental | Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks. |
|
| Placebo capsule | Placebo Comparator | Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sarcosine Capsule | Dietary Supplement | Sarcosine is a glycine transporter-1 (GlyT-1) inhibitor. By blocking glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor function. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Unified Parkinson's Disease Rating Scale (UPDRS) From Baseline to 8 Weeks. | Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline to 8 weeks. The UPDRS score has three parts, part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living) and Part III (Motor Examination). Each consisting of questions answered on a 0-4 point scale. The minimum total score possible is 0 and the maximum total score possible is 176. Higher scores indicating more severe symptoms. | baseline to 8 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Cognitive Abilities Screening Instrument (CASI) From Baseline to 8 Weeks. | The Cognitive Abilities Screening Instrument (CASI) has a score range of 0 to 100 and provides quantitative assessment on attention, concentration, orientation, short-term memory, long-term memory, language abilities, visual construction, list-generating fluency, abstraction, and judgment. With a higher score indicating Symptom improvement. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Brain Imaging by 18F-FDG PET From Baseline to 8 Weeks. | 18F-FDG PET scan : 8 patients for treatment and placebo groups,respectively. | baseline to 8 weeks |
| Change in Brain Imaging by [99mTc]TRODAT-1 From Baseline to 8 Weeks. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chon-Haw Tsai, MD, PHD | Department of Neurology, China Medical University Hospital, Taichung, Taiwan | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| China Medical University Hospital/Neuro Depart. | Taichung | Taiwan |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24612097 | Derived | Tsai CH, Huang HC, Liu BL, Li CI, Lu MK, Chen X, Tsai MC, Yang YW, Lane HY. Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia. Psychiatry Clin Neurosci. 2014 Sep;68(9):692-700. doi: 10.1111/pcn.12175. Epub 2014 Apr 14. |
Not provided
Not provided
The diagnosis of PD-D was based on the criteria proposed by 2007 movement disorders PD-D task force. 30 patients were enrolled.
Date of recruitment period: 05-Aug-2010 to 08-Jun-2012 Type of location: Hospital, Medical China Universities, Neurology clinic.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Sarcosine Capsule | Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks. |
| FG001 | Placebo Capsule | Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo Capsule | Dietary Supplement | Placebo is dextrin composition. |
|
| baseline to 8 weeks |
| Change in Clinical Dementia Rating (CDR) From Baseline to 8 Weeks. | The CDR is a 5-point scale used to characterize six domains of cognitive and functional performance applicable to Alzheimer disease and related dementias: Memory, Orientation, Judgment & Problem Solving, Community Affairs, Home & Hobbies, and Personal Care. With a higher score indicating more severe symptoms. | baseline to 8 weeks |
| Change in Neuropsychiatry Inventory (NPI) From Baseline to 8 Weeks. | The NPI scale has 12 domains: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavior disturbances, and appetite and eating abnormalities. The total score ranges from 0 to 144, where the score for a domain is defined as the product of frequency (range: 1-4) and severity (range: 1-3). Each domain has a maximum score of 12 and with a higher score indicating more severe symptoms. | baseline to 8 weeks |
| Change in Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD) From Baseline to 8 Weeks. | The Behave-AD includes the assessment of symptoms and a global rating of caregiver distress. A total of 25 symptoms in 7 clusters are rated: paranoid and delusional ideation, hallucinations, aggressiveness, activity disturbances, diurnal rhythm disturbances, affective disturbances and anxieties, and phobias. Caregivers rate behavioral symptoms over the preceding 2 weeks on a 0 to 3 scale. The caregiver also determines a global assessment of caregiver distress on a scale of 0 to 3. The maximum score is 75 and with a higher score indicating more severe symptoms. | baseline to 8 weeks |
| Change in Hamilton Depression Rating Scale (HAM-D) From Baseline to 8 Weeks. | The HAM-D is a 21-item rating scaled which includes an emphasis on behavioral symptoms and somatic complaints that neglects self-reported feelings of distress; and an intermingling of frequency and intensity of symptoms. The total score ranges from 0 to 64: ten items are ranked on a scale from 0 to 4; 9 items are ranked 0 to 2; and 2 items are ranked 0 to 3. With a higher score indicating more severe symptoms. | baseline to 8 weeks |
| Change in Beck Depression Inventory-II (BDI-II) From Baseline to 8 Weeks. | The BDI-II is a 21-item self-report questionnaire assessing the current severity of depression symptoms. Each item is scored on a scale of 0 to 3 and the total score ranges from 0 to 63. With a higher score indicating more severe symptoms. | baseline to 8 weeks |
| Change in The 39-item Parkinson's Disease Questionnaire (PDQ-39) From Baseline to 8 Weeks. | The PDQ-39 contains 39-items covering 8 discrete dimensions: mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort. Each question is scored on a 5-point scale and recoded to 0 to 4 for the analysis. The total score can range from 0 to 132 and with a higher score indicating more severe symptoms. | baseline to 8 weeks |
[99mTc]TRODAT-1 : 7 patients for treatment and placebo groups, respectively.
| baseline to 8 weeks |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Sarcosine Capsule | Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks. |
| BG001 | Placebo Capsule | Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in Unified Parkinson's Disease Rating Scale (UPDRS) From Baseline to 8 Weeks. | Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline to 8 weeks. The UPDRS score has three parts, part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living) and Part III (Motor Examination). Each consisting of questions answered on a 0-4 point scale. The minimum total score possible is 0 and the maximum total score possible is 176. Higher scores indicating more severe symptoms. | The Intent-to-Treat (ITT) Population comprised all randomised patients who took at least one dose of study medication or placebo and who had a valid baseline efficacy measure and at least one post-baseline efficacy measure. | Posted | Mean | Standard Deviation | Scores on a scale | baseline to 8 weeks. |
|
|
| |||||||||||||||||||||||||||||||||||
| Secondary | Change in Cognitive Abilities Screening Instrument (CASI) From Baseline to 8 Weeks. | The Cognitive Abilities Screening Instrument (CASI) has a score range of 0 to 100 and provides quantitative assessment on attention, concentration, orientation, short-term memory, long-term memory, language abilities, visual construction, list-generating fluency, abstraction, and judgment. With a higher score indicating Symptom improvement. | ITT Population | Posted | Mean | Standard Deviation | Scores on a scale | baseline to 8 weeks |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change in Clinical Dementia Rating (CDR) From Baseline to 8 Weeks. | The CDR is a 5-point scale used to characterize six domains of cognitive and functional performance applicable to Alzheimer disease and related dementias: Memory, Orientation, Judgment & Problem Solving, Community Affairs, Home & Hobbies, and Personal Care. With a higher score indicating more severe symptoms. | ITT Population | Posted | Mean | Standard Deviation | Scores on a scale | baseline to 8 weeks |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change in Neuropsychiatry Inventory (NPI) From Baseline to 8 Weeks. | The NPI scale has 12 domains: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavior disturbances, and appetite and eating abnormalities. The total score ranges from 0 to 144, where the score for a domain is defined as the product of frequency (range: 1-4) and severity (range: 1-3). Each domain has a maximum score of 12 and with a higher score indicating more severe symptoms. | ITT Population | Posted | Mean | Standard Deviation | Scores on a scale | baseline to 8 weeks |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change in Behavioral Pathology in Alzheimer's Disease Rating Scale (Behave-AD) From Baseline to 8 Weeks. | The Behave-AD includes the assessment of symptoms and a global rating of caregiver distress. A total of 25 symptoms in 7 clusters are rated: paranoid and delusional ideation, hallucinations, aggressiveness, activity disturbances, diurnal rhythm disturbances, affective disturbances and anxieties, and phobias. Caregivers rate behavioral symptoms over the preceding 2 weeks on a 0 to 3 scale. The caregiver also determines a global assessment of caregiver distress on a scale of 0 to 3. The maximum score is 75 and with a higher score indicating more severe symptoms. | Posted | Mean | Standard Deviation | Scores on a scale | baseline to 8 weeks |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Change in Hamilton Depression Rating Scale (HAM-D) From Baseline to 8 Weeks. | The HAM-D is a 21-item rating scaled which includes an emphasis on behavioral symptoms and somatic complaints that neglects self-reported feelings of distress; and an intermingling of frequency and intensity of symptoms. The total score ranges from 0 to 64: ten items are ranked on a scale from 0 to 4; 9 items are ranked 0 to 2; and 2 items are ranked 0 to 3. With a higher score indicating more severe symptoms. | Posted | Mean | Standard Deviation | Scores on a scale | baseline to 8 weeks |
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Change in Beck Depression Inventory-II (BDI-II) From Baseline to 8 Weeks. | The BDI-II is a 21-item self-report questionnaire assessing the current severity of depression symptoms. Each item is scored on a scale of 0 to 3 and the total score ranges from 0 to 63. With a higher score indicating more severe symptoms. | ITT Population | Posted | Mean | Standard Deviation | Scores on a scale | baseline to 8 weeks |
|
| ||||||||||||||||||||||||||||||||||||
| Secondary | Change in The 39-item Parkinson's Disease Questionnaire (PDQ-39) From Baseline to 8 Weeks. | The PDQ-39 contains 39-items covering 8 discrete dimensions: mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort. Each question is scored on a 5-point scale and recoded to 0 to 4 for the analysis. The total score can range from 0 to 132 and with a higher score indicating more severe symptoms. | ITT Population | Posted | Mean | Standard Deviation | Scores on a scale | baseline to 8 weeks |
|
| ||||||||||||||||||||||||||||||||||||
| Other Pre-specified | Change in Brain Imaging by 18F-FDG PET From Baseline to 8 Weeks. | 18F-FDG PET scan : 8 patients for treatment and placebo groups,respectively. | Not Posted | baseline to 8 weeks | ||||||||||||||||||||||||||||||||||||||||||
| Other Pre-specified | Change in Brain Imaging by [99mTc]TRODAT-1 From Baseline to 8 Weeks. | [99mTc]TRODAT-1 : 7 patients for treatment and placebo groups, respectively. | Not Posted | baseline to 8 weeks |
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Sarcosine Capsule | Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks. | 0 | 15 | 1 | 15 | ||
| EG001 | Placebo Capsule | Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks. | 0 | 15 | 1 | 15 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| dizziness | Nervous system disorders |
| |||
| hypersomnia | Nervous system disorders |
|
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| The chief, Department of Neurology | China Medical University Hospital | 8864-22052121 | 5035 | d8079@mail.cmuh.org.tw |
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| D003704 | Dementia |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D012521 | Sarcosine |
| ID | Term |
|---|---|
| D034442 | N-substituted Glycines |
| D005998 | Glycine |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided
| >=65 years |
|
| Male |
|
| V2(4-week) |
|
| V3(8-week) |
|
|
|
|
|
|
|
|